Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

40.18
+0.40001.01%
Volume:531.85K
Turnover:21.26M
Market Cap:7.63B
PE:-11.36
High:40.28
Open:39.93
Low:39.65
Close:39.78
Loading ...

BridgeBio Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
30 Apr

BridgeBio Pharma Q1 Net Income USD -169.608 Million Vs. IBES Estimate USD -179.7 Million

Reuters
·
30 Apr

BridgeBio Pharma Q1 EPS $(0.88) Beats $(0.97) Estimate, Sales $116.60M Beat $61.94M Estimate

Benzinga
·
30 Apr

BridgeBio Pharma options imply 8.2% move in share price post-earnings

TIPRANKS
·
30 Apr

BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential

Insider Monkey
·
29 Apr

Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Valneva (VALN) and BridgeBio Pharma (BBIO)

TIPRANKS
·
29 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
29 Apr

BridgeBio Pharma's Beyonttra Approved in UK for Heart Condition due to Amyloidosis

MT Newswires Live
·
28 Apr

BEYONTTRA® (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM

GlobeNewswire
·
28 Apr

BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET

GlobeNewswire
·
22 Apr

BridgeBio price target raised to $53 from $49 at H.C. Wainwright

TIPRANKS
·
15 Apr

BridgeBio Pharma, Inc. : H.c. Wainwright Raises Target Price to $53 From $49

THOMSON REUTERS
·
15 Apr

Press Release: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
12 Apr

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

Dow Jones
·
11 Apr

BridgeBio Pharma Says Acoramidis Improves Outcomes in Phase 3 ATTR-CM Trial

MT Newswires Live
·
01 Apr

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients With Variant Attr-Cm

THOMSON REUTERS
·
31 Mar

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

GlobeNewswire
·
31 Mar

BridgeBio Pharma Initiated at Buy by Redburn Atlantic

Dow Jones
·
31 Mar

Redburn Atlantic Initiates BridgeBio Pharma at Buy With $50 Price Target

MT Newswires Live
·
31 Mar

Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
31 Mar